Bristol-Myers Squibb Beheer

Beheer criteriumcontroles 3/4

De CEO Bristol-Myers Squibb is Chris Boerner, benoemd in Nov2023, heeft een ambtstermijn van 1.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.46M, bestaande uit 14.9% salaris en 85.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.005% van de aandelen van het bedrijf, ter waarde $ 5.99M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 4.2 jaar.

Belangrijke informatie

Chris Boerner

Algemeen directeur

US$8.5m

Totale compensatie

Percentage CEO-salaris	14.9%
Dienstverband CEO	less than a year
Eigendom CEO	0.005%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Aug 15

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Aug 06

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Jul 27

Bristol Myers Squibb: The More It Drops, The More I Buy

Jul 16

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Jun 13

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Jun 09

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

Jun 03

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

May 23

Bristol-Myers Squibb: A Lost Decade?

May 03

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

Apr 29

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Apr 22

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Apr 12

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Apr 02

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 21

Bristol-Myers Squibb Is Not A Buy For Me

Mar 19

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Mar 07

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 07

Analyse CEO-vergoeding

Hoe is Chris Boerner's beloning veranderd ten opzichte van Bristol-Myers Squibb's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$7b
Jun 30 2024	n/a	n/a	-US$7b
Mar 31 2024	n/a	n/a	-US$6b
Dec 31 2023	US$8m	US$1m	US$8b
Sep 30 2023	n/a	n/a	US$8b
Jun 30 2023	n/a	n/a	US$8b
Mar 31 2023	n/a	n/a	US$7b
Dec 31 2022	US$7m	US$1m	US$6b
Sep 30 2022	n/a	n/a	US$7b
Jun 30 2022	n/a	n/a	US$7b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$7m	US$1m	US$7b
Sep 30 2021	n/a	n/a	-US$5b
Jun 30 2021	n/a	n/a	-US$5b
Mar 31 2021	n/a	n/a	-US$6b
Dec 31 2020	US$6m	US$953k	-US$9b
Sep 30 2020	n/a	n/a	-US$44m
Jun 30 2020	n/a	n/a	-US$563m
Mar 31 2020	n/a	n/a	US$954m
Dec 31 2019	US$6m	US$891k	US$3b

Compensatie versus markt: De totale vergoeding ($USD 8.46M ) Chris } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).

Compensatie versus inkomsten: De vergoeding van Chris is gestegen terwijl het bedrijf verliesgevend is.

CEO

Chris Boerner (53 yo)

less than a year

Tenure

US$8,461,833

Compensatie

Dr. Christopher S. Boerner, also known as Chris, Ph.D. served as Chief Operating Officer at Bristol-Myers Squibb Company since April 26, 2023 to 2023 and served as its Executive Vice President since April...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Boerner	CEO & Chairman	less than a year	US$8.46m	0.0051% $ 6.0m
David Elkins	Executive VP & CFO	5yrs	US$7.17m	0.0096% $ 11.4m
Sandra Leung	Executive VP & General Counsel	17.8yrs	US$5.92m	0.022% $ 26.2m
Samit Hirawat	Executive VP	5.4yrs	US$6.23m	0.0031% $ 3.6m
Greg Meyers	Executive VP and Chief Digital & Technology Officer	2.8yrs	geen gegevens	0.00026% $ 308.0k
Timothy Power	VP & Head of Investor Relations	no data	geen gegevens	geen gegevens
Kimberly Jablonski	Chief Compliance & Ethics Officer	1.1yrs	geen gegevens	geen gegevens
Ahn Poole	Executive Vice President & Chief Human Resources Officer	less than a year	geen gegevens	0.00013% $ 154.0k
Joseph Eiden	Head of Medical Affairs	no data	geen gegevens	geen gegevens
Adam Lenkowsky	Executive VP	no data	geen gegevens	0.00080% $ 947.7k
Catherine Owen Adams	Senior Vice President of Major Markets	no data	geen gegevens	geen gegevens
Karin Shanahan	Executive Vice President of Global Product Development & Supply	2.8yrs	geen gegevens	0.00031% $ 367.2k

2.8yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BMY wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Boerner	CEO & Chairman	1.8yrs	US$8.46m	0.0051% $ 6.0m
Derica Rice	Independent Director	4.2yrs	US$375.00k	0% $ 0
Phyllis Yale	Independent Director	5yrs	US$365.00k	0% $ 0
Peter Arduini	Independent Director	8.6yrs	US$359.68k	0% $ 0
Deepak Bhatt	Independent Director	2.4yrs	US$329.97k	0% $ 0
Theodore Samuels	Lead Independent Director	7.8yrs	US$425.00k	0.0018% $ 2.1m
Paula Price	Independent Director	4.2yrs	US$365.00k	0% $ 0
Julia Haller	Independent Director	5yrs	US$371.68k	0.00067% $ 793.7k
Michael McMullen	Independent director	less than a year	geen gegevens	0.000050% $ 59.2k
Karen Vousden	Independent Director	6.8yrs	US$344.74k	0% $ 0
Manuel Medina	Independent Director	3.4yrs	US$335.00k	0% $ 0

4.2yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BMY wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Bristol-Myers Squibb Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Executive Chairman of the Board exercised options and sold US$3.6m worth of stock

Recent updates

Price target increased by 7.4% to US$58.64

Bristol-Myers Squibb Company Showcases the Continued Strength of Its Cardiovascular Portfolio with New Clinical and Real-World Data At American Heart Association Scientific Sessions 2024

Bristol Myers Squibb Presents New Long-Term Data from the EMERGENT Program Evaluating Covenfy in Adults with Schizophrenia At Psych Congress 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data At Psych Congress 2024

Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren

Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting

Upcoming dividend of US$0.60 per share

Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Bristol Myers Squibb Announces New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® Plus Yervoy® in Advanced Melanoma

Second quarter dividend of US$0.60 announced

Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024

Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows

Bristol Myers Squibb Announces Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (Mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Consensus EPS estimates fall by 18%

Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb: The More It Drops, The More I Buy

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024

First quarter dividend of US$0.60 announced

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial

Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol-Myers Squibb: A Lost Decade?

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Consensus EPS estimates fall by 24%

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease

Upcoming dividend of US$0.60 per share

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Bristol-Myers Squibb Is Not A Buy For Me

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Executive Chairman of the Board exercised options and sold US$3.6m worth of stock

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60